Press Releases

 
Press Releases
Date Title and Summary View
Sep 11, 2012 Additional Clinical Results Expected in Q1 2013 MADISON, Wisc. (September 11, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S...
PDF
Sep 7, 2012 Cancer-Targeted Therapeutic I-131-CLR1404 (HOT) and Diagnostic I-124-CLR1404 (LIGHT) Demonstrate Selective and Prolonged Uptake in a Range of Tumor Types MADISON, Wisc. (September 7, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatme...
PDF
Sep 4, 2012 MADISON, Wisc. (September 4, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Tuesday, ...
PDF
Aug 28, 2012 Expects to File IND in Second Half of 2013 MADISON, Wisc. (August 28, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targe...
PDF
Jun 27, 2012 MADISON, WI, June 27, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the LHA Life Sciences & Medical Technologies Virtual ...
PDF
Jun 19, 2012 Expects Final Imaging Results in the First Quarter 2013 MADISON, WI, June 19, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center (UW...
PDF
Jun 14, 2012 Announces Dismissal with Prejudice of Putative Federal Securities Class Action Lawsuit MADISON, WI, June 14, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a public offering...
PDF
Jun 8, 2012 NOVELOS THERAPEUTICS PRICES $5.4 MILLION PUBLIC OFFERING MADISON, WI, June 8, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 5,420,800 units at $1.00 pe...
PDF
May 15, 2012 First Patient Enrolled in Second Cohort, Additional Clinical Results Expected in Q3 2012 Expects to Begin Phase 2 Proof-of-Concept Trials in Q1 2013 MADISON, WI, May 15, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel...
PDF
Apr 24, 2012 Demonstrates Positive Initial Imaging Results; Additional Clinical Results Expected by mid-2012 MADISON, WI, April 24, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that the University o...
PDF
Page: FirstPrevious ...
15
NextLast